Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

April 28, 2014

Primary Completion Date

May 10, 2017

Study Completion Date

May 10, 2017

Conditions
Smallpox
Interventions
BIOLOGICAL

IMVAMUNE®

0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml

Trial Locations (12)

19104

University of Pennsylvania Clinical Trials Unit, Philadelphia

20009

Dupont Circle Physicians Group, Washington D.C.

32504

Infectious Disease Associats of NW Florida Center for Prevention and Treatment of Infections Infectious Diseases Associates of NW FL, Pensacola

33305

Rowan Tree Medical, Wilton Manors

35294

University of Alabama at Birmingham, Birmingham

52242

University of Iowa Departments of Internal Medicine and Microbiology University of Iowa, Iowa City

60612

University of Illinois - Chicago, Chicago

63110

Washington University School of Medicine, St Louis

72207

Health for Life Clinic Little Rock, Little Rock

94115

Quest Clinical Research, San Francisco

009091711

Clinical Research Puerto Rico, Inc., San Juan

00927

Fundacion de Investigacion, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bavarian Nordic

INDUSTRY

NCT02038881 - Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection | Biotech Hunter | Biotech Hunter